E2F3 and hepatocellular carcinoma: Anti-GPC3-scFv genetically modified MSC-Exos effectively delivered miR-26a into the GPC3-positive HCC cells and suppressed CDK6 and E2F3-dependent proliferation and invasiveness of tumor cells, attenuating growth and progression of HCC in experimental animals without causing any obvious side effects [46].